Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/15/2026 | $10.00 | Neutral → Sell | Goldman |
| 1/9/2026 | $24.00 | Neutral → Buy | BTIG Research |
| 11/3/2025 | $30.00 | Neutral → Buy | H.C. Wainwright |
| 10/2/2025 | Buy → Neutral | H.C. Wainwright | |
| 10/1/2025 | $7.00 | Buy → Neutral | Goldman |
| 9/30/2025 | $2.00 | Outperform → Underperform | Wolfe Research |
| 9/30/2025 | $5.00 | Buy → Neutral | Citigroup |
| 9/29/2025 | $8.00 | Buy → Hold | Jefferies |
Goldman downgraded MoonLake Immunotherapeutics from Neutral to Sell and set a new price target of $10.00
BTIG Research upgraded MoonLake Immunotherapeutics from Neutral to Buy and set a new price target of $24.00
H.C. Wainwright upgraded MoonLake Immunotherapeutics from Neutral to Buy and set a new price target of $30.00
8-K - MoonLake Immunotherapeutics (0001821586) (Filer)
SCHEDULE 13G/A - MoonLake Immunotherapeutics (0001821586) (Subject)
SCHEDULE 13D/A - MoonLake Immunotherapeutics (0001821586) (Subject)
4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
Brings 20+ years of clinical development experience in autoimmune and inflammatory diseases, including OX40/OX40L program leadership Will build and lead Imagene's clinical organization and drive completion of the Phase 2b ADAPTIVE trial in atopic dermatitis Will expand Phase 2b trial footprint with planned international sites including in the UK and Europe SAN DIEGO, Feb. 10, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (NASDAQ:IMA, "Imagene, " or the "Company")), today announced the appointment of Dr. Ben Porter-Brown, a seasoned autoimmune and inflammatory drug developer with experience in the OX40 receptor-ligand (OX40-OX40L) inhibition field, as its Chief Medical Officer. He will be fo
The Dermatology Division of the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to sonelokimab (SLK) in moderate-to-severe palmoplantar pustulosis (PPP) supported by positive results from the Phase 2 LEDA trialThe upcoming Phase 3 program will therefore be expected to benefit from earlier and more frequent interactions with the FDA under the Fast Track program, potentially enabling a more efficient development pathway This regulatory decision follows the recent clear guidance from the FDA, in which the Company confirmed its clinical evidence strategy for the planned submission of a Biologic License Application (BLA) in H2 2026 for SLK in hidradenitis suppurativa (H
DENVER, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Markets head into the session with a familiar but powerful theme in focus: enabling technologies that quietly unlock the next wave of growth. From satellite connectivity at cruising altitude to biologics edging closer to regulatory milestones, and from AI-driven diagnostics to advanced biomaterials, today's news flow highlights companies pushing infrastructure, science, and scale forward at the same time. Connectivity Takes Flight: flyExclusive Embraces Starlink flyExclusive (NYSE:FLYX) is setting a new benchmark in private aviation after being named an authorized Starlink Aviation dealer and installer. The move brings high-speed, low-latency sat
4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
Brings 20+ years of clinical development experience in autoimmune and inflammatory diseases, including OX40/OX40L program leadership Will build and lead Imagene's clinical organization and drive completion of the Phase 2b ADAPTIVE trial in atopic dermatitis Will expand Phase 2b trial footprint with planned international sites including in the UK and Europe SAN DIEGO, Feb. 10, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (NASDAQ:IMA, "Imagene, " or the "Company")), today announced the appointment of Dr. Ben Porter-Brown, a seasoned autoimmune and inflammatory drug developer with experience in the OX40 receptor-ligand (OX40-OX40L) inhibition field, as its Chief Medical Officer. He will be fo
Ended the third quarter with $380.5 million in cash, cash equivalents and short-term marketable debt securities which, together with funds from a previously announced debt-facility, are expected to provide runway into the second half of 2027Reported results of its Phase 2 LEDA clinical trial in Palmoplantar Pustulosis (PPP) where sonelokimab (SLK) demonstrated clinically meaningful and statistically significant benefitReported an interim analysis of the long-term data from the VELA-1 and VELA-2 clinical trials in adults with Hidradenitis Suppurativa (HS), as well as an interim analysis of its VELA-TEEN clinical trial in adolescent HS, demonstrating the potential and competitive benefit of SL
Phase 3 VELA program in hidradenitis suppurativa (HS) on track for an expected primary endpoint readout around September 2025 and an expected submission of a Biologic License Application (BLA) in the United States in mid-2026Other clinical trials of sonelokimab in palmoplantar pustulosis (PPP), axial spondyloarthritis (axSpA), psoriatic arthritis (PsA) and adolescent HS progressing well and expected to support a catalyst-rich roadmap over the next 12 monthsEnded the second quarter with $425.1 million in cash, cash equivalents and short-term marketable debt securities with up to an additional $425 million in non-dilutive funds remaining accessible through previously announced debt-facility Z
MoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business Update Continued to make significant progress with the development of the Nanobody® sonelokimab across portfolio of indications, including Phase 3 studies in hidradenitis suppurativa (HS), psoriatic Arthritis (PsA) and adolescent HS, as well as Phase 2 studies in palmoplantar pustulosis (PPP) and axial spondyloarthritis (axSpA)Announced completion of enrollment of patients in the Phase 3 program in HS (the VELA program) and disclosed baseline characteristics, replicating the Phase 2 MIRA trialPresented an interim readout of the Phase 2 LEDA study in PPP, highlighting the potential of sonelokimab
SC 13G/A - MoonLake Immunotherapeutics (0001821586) (Subject)
SC 13D/A - MoonLake Immunotherapeutics (0001821586) (Subject)
SC 13D/A - MoonLake Immunotherapeutics (0001821586) (Subject)